$6.65
6.47% yesterday
Nasdaq, Apr 04, 10:03 pm CET
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Grifols, S.A. Sponsored ADR Class B Stock price

$6.65
-1.62 19.59% 1M
-2.27 25.45% 6M
-0.79 10.62% YTD
-0.21 3.06% 1Y
-5.52 45.36% 3Y
-12.71 65.65% 5Y
-9.86 59.72% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.46 6.47%
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Key metrics

Market capitalization $1.72b
Enterprise Value $13.05b
P/E (TTM) P/E ratio 26.52
P/B ratio (TTM) P/B ratio 0.74
Cash position $1.01b
P/E forward 8.74
P/S forward 0.21
EV/Sales forward 1.60
Short interest 0.40%

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

1x Buy
33%
1x Hold
33%
1x Sell
33%

Analyst Opinions

3 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
33%
Hold
33%
Sell
33%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,108 2,108
11% 11%
100%
- Direct Costs 1,290 1,290
11% 11%
61%
818 818
10% 10%
39%
- Selling and Administrative Expenses 170 170
35% 35%
8%
- Research and Development Expense 123 123
0% 0%
6%
525 525
47% 47%
25%
- Depreciation and Amortization 117 117
1% 1%
6%
EBIT (Operating Income) EBIT 407 407
70% 70%
19%
Net Profit 74 74
22% 22%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Neutral
Reuters
3 days ago
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial reported on Wednesday, citing unidentified industry sources.
Positive
Seeking Alpha
about one month ago
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential ...
Positive
Reuters
about one month ago
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value.
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today